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losure Is Effective in Improving Migraine in
atients With High-Risk Anatomic and Functional
haracteristics for Paradoxical Embolism
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ilvio Aggio, MD,† Mauro Chinaglia, MD,‡ Giorgio Rigatelli, MD,§ Jack P. Chen, MD
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bjectives In the present study, we sought to assess the effectiveness of migraine treatment by
eans of primary patent foramen ovale (PFO) transcatheter closure in patients with anatomical and
unctional characteristics predisposing to paradoxical embolism without previous cerebral ischemia.
ackground The exact role for transcatheter closure of PFO in migraine therapy has yet to be
lucidated.
ethods We enrolled 86 patients (68 female, mean age 40.0  3.7 years) referred to our center
ver a 48-month period for a prospective study to evaluate severe, disabling, medication-refractory
igraine and documented PFO. The Migraine Disability Assessment Score (MIDAS) was used to as-
ess the incidence and severity of migraine. Criteria for intervention included all of the following:
asal shunt and shower/curtain shunt pattern on transcranial Doppler and echocardiography, pres-
nce of interatrial septal aneurysm and Eustachian valve, 3 to 4 class MIDAS score, coagulation ab-
ormalities, and medication-refractory migraine with or without aura.
esults On the basis of our inclusion criteria, we enrolled 40 patients (34 females, mean age 35.0
6.7 years, mean MIDAS 35.8  4.7) for transcatheter PFO closure; the remainder continued on
revious medical therapy. Percutaneous closure was successful in all cases, with no peri-procedural
r in-hospital complications. After a mean follow-up of 29.2  14.8 months (range 6 to 48 months),
FO closure was complete in 95%; all patients (100%) reported improved migraine symptomatology
mean MIDAS score 8.3  7.8, p  0.03). Speciﬁcally, auras were eliminated in 100% of patients af-
er closure.
onclusions Primary transcatheter PFO closure resulted in a very signiﬁcant reduction in migraine
n patients satisfying our criteria. (J Am Coll Cardiol Intv 2010;3:282–7) © 2010 by the American
ollege of Cardiology Foundation
rom the *Section of Adult Congenital and Adult Heart Disease, Cardiovascular Diagnosis and Endoluminal Interventions,
Division of Cardiology, Echocardiography Lab, and the ‡Department of Neuroscience, Rovigo General Hospital, Rovigo, Italy;
Department of Speciality Medicine, Division of Cardiology, Legnago General Hospital, Verona, Italy; and the Saint Joseph’s
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283igraine is a recurrent, common, and potentially disabling
eadache affecting up to 10% of the population, accounting
or significant morbidity, lost productivity, and health care
xpenditures. Approximately 25% of migraine patients fur-
her suffer from concomitant aura. Beta-blockers, amitrip-
yline, and anticonvulsants attenuate headache intensity and
requency in 30% to 50% of patients (1). Although the
athophysiology of migraine is not fully understood, the
resence of patent foramen ovale (PFO) is believed to play
See page 288
role in the pathophysiology. Some studies have reported a
reater PFO association in subjects with aura, as compared
ith those without (2–3). Although prior nonrandomized
tudies involving nonhomogeneous patient cohorts have
uggested a beneficial role for PFO closure in migraine
herapy, much controversy still lingers regarding this clinical
uestion. It should be noted that the only randomized trial,
he MIST (Migraine Intervention with Starflex Technology)
rial (4), failed to show significant benefit from PFO percuta-
eous closure. However, most previous studies did not identify
lear inclusion criteria; this issue might have negatively im-
acted long-term outcomes. We sought to assess the effective-
ess of migraine therapy with PFO transcatheter closure in
atients without previous cerebral ischemia and with anatomic
nd functional characteristics predisposing to paradoxical
mbolism.
ethods
e enrolled 86 patients (68 women, mean age 40  3.7
ears) who were referred to our center for a 48-month
rospective study to evaluate the correlation between mi-
raine and PFO. The PFO were documented by transtho-
acic echocardiography/transesophageal echocardiography
TEE) as part of migraine evaluation (Table 1). Migraine
as diagnosed according to the International Headache
ociety criteria (5): Migraine Disability Assessment Score
MIDAS) (6) was used to assess the incidence and severity
f migraine headache by an independent neurologist.
nclusion criteria. Criteria for intervention were driven by
uthors’ experience as well as prevailing published data and
ncluded all the following: curtain shunt pattern of right-
o-left (R-L) shunt on transcranial Doppler (TC-D) (7) and
EE, refractory and disabling migraine (with 3 to 4 class
IDAS score) with or without Aura, PFO, R-L shunt
uring normal respiration, atrial septal aneurysm (ASA),
oagulation abnormalities (including Leiden Factor V mu-
ation, methylenetetrahydrofolate reductase [MTHFR]
utation, C and S protein, anticardiolipin and antiphos-
holipid autoantibodies, antithrombin III), and presence of
ustachian valve (EV). Refractory disabling migraine was
efined as migraine with MIDAS 25, refractory to con- ientional drug therapy, including personalized dosage of
eta blockers, antidepressive drugs, tryptan, and anti-
nflammatory medications.
chocardiographic protocols. Transthoracic echocardiogra-
hy and/or TEE was conducted with a GE Vivid 7
General Electric Corp., Norfolk, Virginia) with bubble test
nd Valsalva maneuver under local anesthesia: shunt grad-
ng (grade 0  none, grade 1  1 to 5 bubbles, grade 2 
to 20 bubbles, grade 3  20 bubbles); presence of EV;
nd ASA extension, classified according to Olivares-Reyes
t al. (8), were obtained. Patients meeting criteria for the
tudy were offered an intracardiac echocardiographic guided
FO closure with the mechanical 9-F 9-MHz UltraICE
atheter (EP Technologies, Boston Scientific Corporation,
an Jose, California). The intracardiac echocardiography
ICE) study was conducted as previously described (9), by
erforming a manual pull-back from the superior vena cava
o the inferior vena cava through 5 sectional planes; mea-
urements of diameters of the oval fossa, the entire atrial
eptal length, and rims were ob-
ained with electronic caliper
dge-to-edge in the aortic valve
lane and the 4-chamber plane.
he PFO tunnel length was also
easured, and EV presence was
onfirmed intraprocedurally. In-
racardiac echocardiographic
onitoring of the implantation
rocedure was conducted in the
-chamber plane.
evice selection process. On the
asis of ICE findings and mea-
urements, the operators se-
ected either the Amplatzer Oc-
luder family (PFO Occluder,
ribriform Occluder, or ASD Occluder, AGA Medical
orporation, Golden Valley, Minnesota) or the Premere
losure System (St. Jude Medical Incorporated, St. Paul,
innesota). The Amplatzer PFO Occluder was selected
hen the ASA was bidirectional with moderate motion (3
-L or 3 left-to-right ASA). The Premere occlusion system
as chosen in cases of absent, motionless, or unidirectional
SA (1 R, 2 L ASA); when PFO tunnel length was 10
m; and in all cases of thick septum secundum (thickness
10 mm). The Amplatzer Cribriform Occluder was se-
ected in cases of multi-perforated ASA. Care was taken to
ross the most central hole in the oval fossa with the
uidewire during ICE guidance, as previously described
10). These devices were also selected for huge and bidirec-
ional ASA (4 to 5 R-L ASA) to ensure as-complete-as-
ossible coverage of the oval fossa on both sides of the
nteratrial septum. Device size selection involved ensuring
hat the entire left disk diameter did not exceed the entire
Abbreviations
and Acronyms
ASA  atrial septal
aneurysm
EV  Eustachian valve
ICE  intracardiac
echocardiography
MIDAS  Migraine Disability
Assessment Score
PFO  patent foramen ovale
R-L  right-to-left
TC-D  transcranial Doppler
TEE  transesophageal
echocardiographynteratrial septal length on ICE measurement.
F
T
6
r
H
a
w
e
a
v
a
r
o
r
S
p
c
a
(
C
s
R
O
p
M
t
m
d
t
o
b
w
m
p
w
I
s
d
1
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 3 , 2 0 1 0
M A R C H 2 0 1 0 : 2 8 2 – 7
Rigatelli et al.
Migraine and PFO Anatomy
284ollow-up protocol. Follow-up was conducted by means of
EE at 1 month and, if even a small shunt was detected, at
months as well. Additionally, transthoracic echocardiog-
aphy at 1 month and 6 and 12 months; TC-D at 1 month;
olter monitoring at 1 month; and clinic visit at 1 month
nd 6 and 12 months were also performed. Residual shunt
as assessed by contrast TEE and TC-D (11). The MIDAS
valuation was performed at 6 and 12 months and yearly
fter the first year after implantation; patients were inter-
iewed regarding reduction or abolition of migraine and
ura with a 4-grade scale: 100% (total resolution), 50%
eduction, 25% reduction, or 0% (unchanged). A minimum
f 6-month follow-up was required for inclusion in the final
esults.
tatistical analysis. Chi-square, analysis of variance, and
aired Student t tests were used to compare frequencies and
Table 1. Patient Characteristics: PFO Closure Versus Medical Therapy
Mean or %
p Value
Medical
(n  46)
Closure
(n  40)
Age (yrs) 40 3.7 38.9 5.8 ns
Female 35/46 (76.0) 34/40 (85) ns
Migraine with aura 10/46 (21.7) 32/40 (80) 0.01
Blurred vision, hemianopsia,
cortical blindness
7/46 (15.2) 27/40 (67.5) 0.01
Hemilateral loss of strength
and paresthesias
3/46 (6.5) 5/40 (12.5) ns
Migraine with no aura 36/46 (78.2) 8/40 (20) 0.01
MIDAS classes 1–2 38/46 (82.6) 0/40 (0) 0.01
MIDAS classes 3–4 8/46 (17.3) 40/40 (100) 0.01
R-L shunt grade 1 31/46 (67.4) 0/40 (0) 0.01
Mean number of migraine
without aura attacks/month
2.0 0.7 1.1 0.2 0.01
Mean number of migraine with
aura attacks/month
0 4.2 0.8 0.01
R-L shunt grade 2 11/46 (23.9) 18/40 (45) 0.04
R-L shunt grade 3 4/46 (8.7) 22/40 (55) 0.01
TC-D trivial shunt (15 bubbles) 27/46 (58.7) 0/40 (0) 0.01
TC-D shower pattern 13/46 (28.2) 21/40 (52.5) 0.02
TC-D curtain pattern 6/46 (13.0) 19/40 (47.5) 0.01
Interatrial septal aneurysm
(on TEE)
13/46 (6.5) 40/40 (100) 0.01
White-matter lesion on
cerebral MRI
11/46 (
23.9)
25/40 (62.5) 0.01
Deﬁciency of anti-thrombin III,
protein C, S
0/46 (0) 8/40 (20) 0.01
Factor V Leiden 1/46 (2.2) 6/40 (15) 0.01
Antiphospholipid or
anticardiolipin
0/46 (0) 3/40 (7.5) 0.01
Hyperhomocysteinemia 7/46 (15.2) 23/40 (57.5) 0.01
MIDAS  Migraine Disability Assessment Score; MRI  magnetic resonance imaging; PFO 
patent foramen ovale; R-L  right-to-left; TC-D  transcranial Doppler; TEE  transesophageal
echocardiography.ontinuous variables between and within groups. Statisticalnalysis was performed with a statistical software package
SAS for Windows, version 8.2, SAS Institute, Cary, North
arolina). A p value of 0.05 was considered to be
tatistically significant.
esults
n the basis of all the inclusion criteria, we enrolled 40
atients (34 female, mean age 35  6.7 years, mean
IDAS score 35.8  4.7) for transcatheter PFO closure;
he remainder were referred to the neurology service for
edical therapy, which included beta blockers, anti-
epressive drugs, tryptan, and anti-inflammatory medica-
ions. All patients were informed of and consented to the
ff-label nature of the intervention. The study was approved
y the local internal review board and ethics committee.
The procedure was successful in all patients (Tables 2 and 3)
ith no peri-procedural or in-hospital complications. At a
ean follow-up of 29.2  14.8 months (range 6 to 48), all
atients experienced symptomatic improvement (Figs. 1 and 2)
ith a mean MIDAS score of 8.3 7.8 (p 0.03) (Fig. 3).
n contrast, the MIDAS scores of excluded subjects as-
igned to medical therapy remained essentially unchanged
uring the same follow-up period (22.6 7.1 at baseline vs.
9.1  8.2 in the follow-up, p  0.059). Complete PFO
Table 2. Intracardiac Echocardiographic Measurements of Anatomic
Features of the Interatrial Septum
Anatomical characteristics
Diameter of the interatrial septum 37 10.6
Length of anterosuperior rim (aortic rim) 5.8 1.1
Oval fossa diameter 23 7.9
Patent oval foramen tunnel length 13 4.9
Patent oval foramen size 6.1 0.4
Rim thickness 10.2 8.6
Association of anatomical characteristics
Long channel alone 8 (20%)
Large ASA ( 4 R-L) alone 14 (35%)
Moderate ASA (2 R-L but4 R-L) alone 9 (22.5%)
Hypertrophic rims alone 4 (10%)
Long channelmoderate ASA 3 (7.5%)
Long channel hypertrophic rims 2 (5%)
Values are mean SD or n (%). Measurements are referred to the 4-chamber view.
ASA atrial septal aneurysm; other abbreviations as in Table 1.
Table 3. Device Type and Size Selection
Device 18 mm 20 mm 25 mm 35 mm
Amplatzer PFO — — 7 1
Amplatzer MF — — 14 —
Premere — 9 9 —
Values are n (number of patients).MFmultifenestrated; PFO patent foramen ovale.
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285losure was observed in 95% of patients on TEE and TC-D
ltrasound. In particular, at follow-up, aura disappeared in
00% of patients with pre-procedural aura.
Figure 1. Enrollment and Follow-Up
Enrollment and follow-up results: 15 patients (pts) decreased the number of m
in 10 patients, beta-blockers in 5 patients).
Figure 2. Migraine Improvement
Histogram representation of migraine with and without aura improvement
after the previously described 4-grade scale in patients (pts) submitted to
transcatheter closure.Two patients (5%) had a persistent small shunt on TEE
both patients had an Amplatzer ASD Cribriform Occluder
5 mm). Two other patients (5%) developed atrial fibrilla-
ion during the early post-procedural period and were
tions from 3 (anti-inﬂammatory, beta-blocker, tryptan) to 1 (anti-inﬂammatory
Figure 3. MIDAS Reduction
Scatter diagram demonstrating the Migraine Disability Assessment Scoreedica(MIDAS) reduction for each single patient: each patient has different color line.
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286reated with antiarrhythmic drugs with restoration of sinus
hythm (1 patient with an Amplatzer ASD Cribriform 30
m, and 1 patient with a Premere Occlusion system 20
m). No aortic erosion or device thrombosis was observed
uring follow-up.
iscussion
ur results suggests that patients with anatomic and func-
ional characteristics highly predictive of paradoxical embo-
ism responded very favorably to transcatheter PFO closure
ith significant symptomatic improvement or even cure.
hese benefits are maintained over long-term follow-up.
oreover, no appreciable symptomatic relief was observed
n the excluded patients, who were relegated to optimal
edical therapy alone and served as a quasi-control arm.
aken collectively, the inclusion criteria might be helpful in
redicting migraine patients most likely to respond to PFO
losure.
Albeit rare, the potential complications of device-based
losure (12) such as erosion, thrombosis, arrhythmias, and
ilent cerebral embolization during implantation as well as
he incompletely investigated nickel hypersensitivity reac-
ion all mandate meticulous patient selection and solid
linical justification for consideration of such procedures.
he inclusion criteria of the recent MIST trial included:
inimum 1-year history, 5 or more days of migraine/
onth, aura, symptoms refractory to 2 preventative medi-
ations, moderate-to-large PFO assessed only by TEE, and
aintenance of prophylactic medications (4). Patients with
oagulation abnormalities or with a serious risk of paradox-
cal embolization were excluded. The degree of shunt on
C-D was not included in the decision-making process.
oreover, a single device type of different sizes was im-
lanted regardless of specific patients’ interatrial septum
haracteristics.
As we suggested previously, to achieve widespread accep-
ance, primary percutaneous closure of PFO to treat mi-
raine—a potentially debilitating but nonetheless nonlife
hreatening condition—must demonstrate a substantial
enefit-to-risk ratio. To this end, our findings seem to
upport primary PFO closure for patients satisfying high-
isk clinical and anatomic features for paradoxical embolism.
Recent studies have demonstrated that basal shunt and
edium-to-large shunts, particularly when associated with
igraine or coagulation abnormalities, are correlated with
n increased risk of paradoxical embolism (13,14). Addition-
lly, shower or curtain shunt patterns are usually detected in
atients with previously presumed paradoxical embolism (15).
astry et al. (16) suggested that only medium-to-large shunts
re related to stroke risk, whereas Anzola et al. (17)
emonstrated that migraine with aura is closely correlated
ith medium and large shunts. Moreover, anatomic char-cteristics such as ASA (18–20) and large EV (21) have pimilarly been correlated with an increased risk of paradox-
cal embolism. Santamarina et al. (22) observed that an
embolic” pattern was significantly (p  0.01) more fre-
uently seen in PFO with ASA patients (n  37; 44%) as
ompared with PFO without ASA (n  22; 26.2%) or no
bnormalities (n  25; 29.8%) on TEE.
In previous series, our group reported that in patients
ith prior stroke, several anatomic and clinical criteria
ight be predictive of responders to percutaneous PFO
losure for migraine therapy (23,24). In the current study,
e applied those similar criteria in a population without
revious cerebral paradoxical embolism: curtain shunt pat-
ern of R-L shunt on TC-D and TEE, PFO, R-L shunt
uring normal respiration, ASA, coagulations abnormali-
ies, and presence of EV. According to the microembolic
ypothesis and the chemical embolism theory, these same
haracteristics have been previously linked to migraine,
specially migraine with aura (15,17,21,22).
We observed, in contrast to other studies (25–31), total
radication of aura in all patients with pre-procedural aura.
ne purely speculative explanation might be that aura itself
s related to certain anatomic and functional characteristics
f the right atrium including large R-L shunt, ASA, and
V, independent of any association with migraine.
Moreover, white matter lesions on magnetic resonance
maging was not a mandatory inclusion criterion in our
eries—differing from most recent series, including the
tudy by Vigna et al. (30). The nature of these lesions is still
nder debate; it is yet unclear whether they represent
mbolic ischemic foci versus alternating vasodilatory and
asoconstrictive cycles typical of migraine itself. Finally,
ompared with most studies in current published reports,
ur study included a minimum of 6-month follow-up as
ell as a longer global follow-up.
tudy limitations. We recognized several limitations to our
tudy. Firstly, our patient sample size was small; however,
e had set fairly stringent inclusion criteria, thereby limiting
nrollment. Also, this was a single-center trial. The non-
andomized nature was clearly a limitation. Nonetheless, we
ere able to follow a surrogate “quasi-” control group, the
xcluded patients assigned to medical therapy alone, and
bserved a dramatic difference in symptomatic response. As
ith any invasive intervention evaluation absent a sham
rm, the potential for placebo bias cannot be fully ignored.
his issue is particularly pertinent when outcomes relate to
ubjectively reported symptomatic improvements.
onclusions
iven the nonlife-threatening nature of migraines, patient
election for percutaneous PFO closure should probably be
eserved for cases of disabling and medically refractory
ymptomatology. Our findings seem to support the pro-
osed high-risk clinical and anatomic features for paradox-
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287cal embolism as markers of response to transcatheter
losure. Before consideration for clinical application, future
arge-scale, multicenter, randomized evaluations are needed
or further confirmation of our preliminary results.
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